|
1.
|
Noguchi N, Kakuma T, Uemura H, et al: A
randomized phase II trial of personalized peptide vaccine plus low
dose estramustine phosphate (EMP) versus standard dose EMP in
patients with castration resistant prostate cancer. Cancer Immunol
Immunother. 59:1001–1009. 2010. View Article : Google Scholar
|
|
2.
|
Terasaki Y, Shichijo S, Nui Y, et al: An
HLA-A3-binding prostate acid phosphatase-derived peptide can induce
CTLs restricted to HLA-A2 and -A24 alleles. Cancer Immunol
Immunother. 58:1877–1885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Mohamed RE, Naito M, Terasaki Y, et al:
Capability of SART3109–118 peptide to induce cytotoxic
T-lymphocytes from prostate cancer patients with HLA class I-A11,
-A31 and -A33 alleles. Int J Oncol. 34:529–536. 2009.
|
|
4.
|
Niu Y, Komatsu N, Komohara K, et al: A
peptide derived from hepatitis C virus (HCV) core protein inducing
cellular responses in patients with HCV with various HLA class IA
alleles. J Med Virol. 81:1232–1240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Niu Y, Terasaki Y, Komatsu N, Noguchi M,
Shichijo S and Itoh K: Identification of peptides applicable as
vaccines for HLA-A26-positive cancer patients. Cancer Sci.
100:2167–2174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Matsueda S, Takedatsu H, Yao A, et al:
Identification of peptide vaccine candidates for prostate cancer
patients with HLA-A3 supertype alleles. Clin Cancer Res.
11:6933–6943. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Takedatsu H, Shichijo S, Katagiri K,
Sawamizu H, Sata M and Itoh K: Identification of peptide vaccine
candidates sharing among HLA-A3+, -A11+,
-A31+, and -A33+ cancer patients. Clin Cancer
Res. 10:1112–1120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Minami T, Matsueda S, Takedatsu H, et al:
Identification of SART3-derived peptides having the potential to
induce cancer-reactive cytotoxic T lymphocytes from prostate cancer
patients with HLA-A3 supertype alleles. Cancer Immunol Immunother.
56:689–698. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Matsueda S, Takedatsu H, Sasada T, et al:
New peptide vaccine candidates for epithelial cancer patients with
HLA-A3 supertype alleles. J Immunother. 30:274–281. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Naito M, Komohara Y, Ishihara Y, et al:
Identification of Lck-derived peptides applicable to anti-cancer
vaccine for patients with human leukocyte antigen-A3 supertype
alleles. Br J Cancer. 97:1648–1654. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Yao A, Harada M, Matsueda S, et al:
Identification of parathyroid hormone-related protein-derived
peptides immunogenic in human histocompatibility leukocyte
antigen-A24+ prostate cancer patients. Br J Cancer.
91:287–296. 2004.
|
|
12.
|
Torikai H, Akatsuka Y, Miyauchi H, et al:
The HLA-A*0201-restricted minor histocompatibility
antigen HA-1H peptide can also be presented by another HLA-A2
subtype, A*0206. Bone Marrow Transplant. 40:165–174.
2007.
|
|
13.
|
Steven NM, Annels NE, Kumar A, Leese AM,
Kurilla MG and Rickinson AB: Immediate early and early lytic cycle
proteins are frequent targets of the Epstein-Barr virus-induced
cytotoxic T cell response. J Exp Med. 185:1605–1607. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Lee SP, Tierney RJ, Thomas WA, Brooks JM
and Rickinson AB: Conserved CTL epitopes within EBV latent membrane
protein 2. A potential target for CTL-based tumor therapy. J
Immunol. 158:3325–3334. 1997.PubMed/NCBI
|
|
15.
|
Parker KC, Bednarek MA, Hull LK, et al:
Sequence motifs important for peptide binding to the human MHC
class I molecule, HLA-A2. J Immunol. 149:3580–3587. 1992.PubMed/NCBI
|
|
16.
|
Ikeda-Moore Y, Tomiyama H, Miwa K, et al:
Identification and characterization of multiple HLA-A24-restricted
HIV-1 CTL epitopes: strong epitopes are derived from V regions of
HIV-1. J Immunol. 159:6242–6252. 1997.PubMed/NCBI
|
|
17.
|
Rammensee HG, Flak K and Rotzschke O:
Peptides naturally presented by MHC class I molecules. Annu Rev
Immunol. 11:213–244. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Hida N, Maeda Y, Katagiri K, Takasu H,
Harada M and Itoh K: A simple culture protocol to detect
peptide-specific cytotoxic T lymphocyte precursors in the
circulation. Cancer Immunol Immunother. 51:219–228. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Jordan MA and Wilson L: Microtubules and
actin filaments: dynamic targets for cancer chemotherapy. Curr Opin
Cell Biol. 10:123–130. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Hashimoto Y, Tajima O, Hashiba H, Nose K
and Kuroki T: Elevated expression of secondary, but not early,
responding genes to phorbol ester tumor promoters in papillomas and
carcinomas of mouse skin. Mol Carcinog. 3:302–308. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Kato K, Ito H, Inaguma Y, Okamoto K and
Saga S: Synthesis and accumulation of αB crystallin in C6 glioma
cells is induced by agents that promote the disassembly of
microtubules. J Biol Chem. 271:26989–26994. 1996.
|
|
22.
|
Cucchiarelli V, Hiser L, Smith H, et al:
Beta-tubulin isotype classes II and V expression patterns in
non-small cell lung carcinomas. Cell Motil Cytoskeleton.
65:675–685. 2008. View Article : Google Scholar : PubMed/NCBI
|
